SoftOx Solutions AS (OSL:SOFTX) Margin of Safety % (DCF FCF Based): N/A (As of Jul. 08, 2026)


What is SoftOx Solutions AS Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

SoftOx Solutions AS's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

OSL:SOFTX vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, SoftOx Solutions AS's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SoftOx Solutions AS Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SoftOx Solutions AS's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where SoftOx Solutions AS's Margin of Safety % (DCF FCF Based) falls into.


SoftOx Solutions AS Business Description

Other Exchanges 6FV:Germany
Address Fridtjof Nansens vei 16, Lysaker, NOR, 1366
SoftOx Solutions AS is a clinical-stage pharmaceutical company. It offers antimicrobial solutions for Wound and Skin Care. It has developed an effective antimicrobial solution to combat biofilm, viral, and antimicrobial-resistant infections. The technology is based on extensive research and development in partnership with Nordic research institutes.